Abstracts Archive - Page 621 of 2607 - ACR Meeting Abstracts

Abstract Number: 2073 • ACR Convergence 2022
The Incidence of COVID-19 Infection in an SLE Cohort, and Its Association with Immunosuppressants, SLE Disease Activity, Vaccination Status, and COVID-19 Antibodies
Laurence S Magder¹, Andrea Fava², Daniel W. Goldman³ and Michelle Petri³, ¹University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: An important clinical question is whether treatments (e.g, corticosteroids, immunosuppressants) or SLE disease activity are associated with an increased risk of COVID-19 infection among…
Abstract Number: 2068 • ACR Convergence 2022
All-Cause Mortality in a Systemic Lupus Erythematosus Cohort
Michelle Petri¹, Joseph Levy², Urbano Sbarigia³ and Daniel W. Goldman¹, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johnson & Johnson, Beerse, Belgium
Background/Purpose: Multiple studies have documented that patients with SLE have a higher all-cause mortality. Active disease contributes to early deaths with later deaths more likely…
Abstract Number: 2083 • ACR Convergence 2022
A Network Meta-analysis on 532 SLE Patients: Low Complement Levels in the First Trimester Predict Disease Flare in Pregnancy
Massimo Radin¹, Irene Cecchi², Francesca Crisafulli³, Evandro Mendes Klumb⁴, Guilherme Ramires De Jesús⁴, Miguel Ángel Saavedra⁵, Geraldine Vanessa Reyes-Navarro⁶, Luca iaccarino⁷, Maddalena Larosa⁷, Gabriella Moroni⁸, Francesco Tamborini⁹, dario Roccatello¹, Laura Andreoli³, Cecilia Beatrice Chighizola¹⁰ and Savino Sciascia², ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy, ³University of Brescia, Brescia, Italy, ⁴Instituto Fernandes Figueira, Rio De Janeiro, Brazil, ⁵Hospital de Especialidades Dr. Antonio Fraga Mouret, Ciudad de México, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁷University of Padova, Padova, Italy, ⁸Humanitas University, Rozzano, Italy, ⁹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁰University of Milan, Milano, Italy
Background/Purpose: The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); decrease in C3 and C4 levels correlates with disease activity…
Abstract Number: 2082 • ACR Convergence 2022
A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
Dario Roccatello¹, Savino Sciascia², Carla Naretto¹, Mirella Alpa¹, Roberta Fenoglio¹, Michela Ferro¹, Giacomo Quattrocchio¹, Elena Rubini¹, Elnaz Rahbani¹, Vittorio Modena¹ and Daniela Rossi¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of…
Abstract Number: 2072 • ACR Convergence 2022
Estimating Corticosteroid-Related Morbidity in Lupus Nephritis: The Glucocorticoid Toxicity Index
Ilana Usiskin and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Patients with lupus nephritis (LN) are often treated with high doses of glucocorticoids and experience glucocorticoid-related toxicity. Quantifying this toxicity may be a useful…
Abstract Number: 2078 • ACR Convergence 2022
Mesangial Lupus Nephritis: Long Term Outcomes
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Mesangial lupus nephritis (LN class II) is generally considered benign with minimal potential for developing advanced chronic kidney disease (CKD). However, a certain proportion…
Abstract Number: 2090 • ACR Convergence 2022
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
Alan Cheng¹, Vibeke Strand², Jiandong Su³, Nicole Anderson³, Lee S Simon⁴ and Zahi Touma³, ¹Michael G. DeGroote School of Medicine, McMaster University, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴SDG LLC, West Newton, MA
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone…
Abstract Number: 2085 • ACR Convergence 2022
Effect of Osteoporosis on Major Adverse Cardiovascular Events (MACEs) and Mortality in Systemic Lupus Erythematosus: A Longitudinal Study
Chi Chiu Mok¹, Kar Li Chan², Ling Yin Ho³ and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Tsing Yi, Hong Kong, China, ³Tuen Mun Hospital, Hong Kong SAR, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the effect of osteoporosis on major adverse cardiovascular events (MACEs) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus…
Abstract Number: 2087 • ACR Convergence 2022
Prospective Study of Clinical, Laboratory, and Patient-Reported Outcomes of Patients with Systemic Lupus Erythematosus Undergoing Total Hip and Total Knee Arthroplasty
David Fernandez, Insa Mannstadt, Mark Figgie, Peter Sculco, Jason Blevins, Caroline Siegel, Deanna Jannat-Khah, DrPH, MSPH, Carey Ford, Mikhail Olferiev, Dina Greenman, Kyriakos Kirou and Susan Goodman, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with SLE have doubled their utilization of THA and TKA, yet postoperative complications remain high. However, disease specific measures have not been assessed.…
Abstract Number: 2091 • ACR Convergence 2022
Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa Parra¹, Jose Meade Aguilar¹, Cynthia Crowson², Cassondra Hulshizer¹, Tina Gunderson¹, Alanna Chamberlain¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence…
Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 2095 • ACR Convergence 2022
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
Laura Cáceres¹, Iñigo Rúa-Figueroa¹, Norman Jimenez², María Galindo-Izquierdo³, Jaime Calvo⁴, Raul Menor Almagro⁵, Antonio Fernandez-Nebro⁶, Julia Martinez-Barrio⁷, Esther Rodriguez Almaraz³, Esther Uriarte Isacelaya⁸, Elena Aurrecoechea⁹, Natalia Mena Vazquez⁶, José Miguel Senabre¹⁰, José Antonio Bernal¹¹, Ana Pérez¹², Vicente Torrente¹³, F. Javier Narváez¹⁴, Clara Sangüesa¹⁵, Marta Arévalo¹⁶, Mercedes Freire¹⁷, Clara Moriano¹⁸, Carlota Iñiguez¹⁹, Eva Tomero Muriel²⁰, José Luis Andreu²¹, Mª Jesús García²², Tatiana Cobo²³, Gema Bonilla²⁴, Nuria Lozano²⁵, Loreto Horcada²⁶, Carlos Montilla²⁷, Lorena Expósito²⁸, María Esther Ruiz²⁹, José Eloy Oller³⁰, Ángela Pecondón³¹, Javier Loricera³², Francisco Javier Novoa³³, Eva Salgado³⁴, Tarek Carlos Salman-Monte³⁵, Alejandro Muñoz³⁶, Jorge J Fragío Gil³⁷ and Jose M Pego-Reigosa³⁸, ¹Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ²IRIDIS Group, Vigo, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de Araba, Vitoria, Spain, ⁵Hospital Jerez de la Frontera, Cádiz, Spain, ⁶Regional University Hospital of Málaga, Málaga, Spain, ⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Hospital Universitario Donostia, Donostia, Spain, ⁹Hospital de Sierrallana, Torrelavega, Spain, ¹⁰Hospital Marina Baixa, Villajoyosa, Spain, ¹¹Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹²University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ¹³Hospital de Sant Joan Despí Moisès Broggi/Consorci Sanitari Integral (CSI), Sant Joan Despí, Spain, ¹⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, ¹⁷Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁸Complejo Asistencial Universitario de León, León, Spain, ¹⁹Hospital Universitario Lucus Augusti, Division of Rheumatology, Lugo, Spain, ²⁰Hospital Universitario La Princesa, Madrid, Spain, ²¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²²Hospital Universitario Ramón y Cajal, Madrid, Spain, ²³Hospital Infanta Sofía, San Sebastián de los Reyes, Spain, ²⁴Hospital Universitario La Paz, Madrid, Spain, ²⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ²⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ²⁷Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Universitario de Canarias, La Laguna, Spain, ²⁹Hospital Universitario de Basurto, Bilbao, Spain, ³⁰Hospital Universitario Dr. Peset, València, Spain, ³¹Hospital Universitario Miguel Servet, Zaragoza, Spain, ³²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Complejo Hospitalario Universitario Insular de Gran Canarias, Las Palmas de Gran Canaria, Spain, ³⁴Complejo Hospitalario De Orense, Ourense, Spain, ³⁵Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ³⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³⁷Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ³⁸Hospital Meixoeiro, Vigo, Spain
Background/Purpose: There is currently no agreement on which scale should be used to evaluate SLE disease activity. The aim of this study was to analyze…
Abstract Number: 2092 • ACR Convergence 2022
Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
Avira Som¹, Lily McMorrow¹, Ling Chen¹, Deepali Sen¹, Alia El-Qunni¹, Elizabeth Baker² and Alfred Kim¹, ¹Washington University School of Medicine, St. Louis, MO, ²Saint Louis University College for Public Health and Social Justice, St. Louis, MO
Background/Purpose: Patients with SLE experience substantial health disparities. Studying the effect of spatial context on health outcomes has become a focus in health disparities research.…
Abstract Number: 2093 • ACR Convergence 2022
Hazard Index Equations Using Data Collected at Baseline and After One Year Treatment Allow Early Prediction of Poor Outcome in an Incident Lupus Nephritis Population: Data from the Louvain Lupus Nephritis Cohort
Farah Tamirou and Frédéric A. Houssiau, Cliniques Universitaires Saint-Luc, Brussels, Belgium
Background/Purpose: While long-term follow-up (FU) is needed to unmask poor outcome in lupus nephritis (LN), most clinical trials evaluate outcome measures at short-term. Early endpoints…
Abstract Number: 1719 • ACR Convergence 2022
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
Yen Po Tsao¹, Fang-Yu Tseng², Ming-Han Chen³ and SZUTING CHEN², ¹Taipei Veterans General Hospital, Taipei, Taiwan, ²National Yang Ming Chao Tung University, Taipei, Taiwan, ³Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease that interferon (IFN) signature involved in the progress. NLRP12 (NOD-like receptor family (NLR) pyrin domain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].